ERBB2 and breast carcinoma: Among other studies, the ToGA-trial demonstrated HER-2 positivity in about 20–30% of adenocarcinomas of the stomach and gastro-esophageal junction [22], and a survival benefit upon treatment with trastuzumab using a specifically modified immunohistochemistry (IHC) scoring algorithm, which differed from breast cancer [20].